Eurofins Genomics

ASPR's IBx Portfolio

Product: Testing Reagents

Description of Project: Eurofins Genomics US was contracted to build a new production facility and expand capacity for the manufacturing of reagents used in COVID-19 diagnostic tests.

Unique Impact: The new facility will focus on the production of GMP grade synthetic DNA, also called oligonucleotides (oligos), for molecular diagnostic testing. Molecular testing is an extremely accurate method for identifying viruses and utilized by a wide array of different applications. In fact, all PCR-based COVID-19 tests are based on molecular technology and accredited as the most reliable type of COVID-19 test. Oligos are a key reagent in molecular diagnostic testing but vulnerable to supply shortages.

Base Award Amount: $30,000,000.00

Category: Testing Capacity and Raw Materials